Literature DB >> 17251312

Systemic inflammation and decline in lung function in a general population: a prospective study.

Andrew W Fogarty1, Stuart Jones, John R Britton, Sarah A Lewis, Tricia M McKeever.   

Abstract

BACKGROUND: An increase in levels of C-reactive protein (CRP), a marker of systemic inflammation, is associated with reduced forced expiratory volume in 1 s (FEV1), supporting the hypothesis that the pathophysiology of chronic obstructive pulmonary disease has a systemic inflammatory component. However, few large studies have assessed the relationship between systemic inflammation as measured by CRP and decline in lung function prospectively in a randomly selected population.
METHODS: In 1991, data were collected on FEV1 and forced vital capacity (FVC) and a blood sample was taken from 2442 randomly selected adults in a community-based cohort. In 2000 these measures were repeated in 1301 individuals. The level of serum CRP was analysed in these samples from 1991 and 2000.
RESULTS: In cross-sectional analyses of data from 1991 and 2000, serum CRP levels were inversely related to FEV1 and FVC. After adjustment for smoking and other confounders, the difference in FEV1 was reduced by -9 ml (95% CI -13 to -5) and -7 ml (95% CI -13 to -2) for each mg/l increment in serum CRP in 1991 and 2000, respectively. There was no significant association between baseline serum CRP levels and decline in FEV1 and FVC over 9 years.
CONCLUSIONS: Although serum CRP levels are inversely associated with lung function in cross-sectional studies, there was no effect of a marker of systemic inflammation on decline in lung function over 9 years.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17251312      PMCID: PMC2117221          DOI: 10.1136/thx.2006.066969

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  28 in total

1.  Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients.

Authors:  D J Clark; B J Lipworth
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

2.  C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.

Authors:  S F P Man; J E Connett; N R Anthonisen; R A Wise; D P Tashkin; D D Sin
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

3.  C-reactive protein in patients with COPD, control smokers and non-smokers.

Authors:  V M Pinto-Plata; H Müllerova; J F Toso; M Feudjo-Tepie; J B Soriano; R S Vessey; B R Celli
Journal:  Thorax       Date:  2005-09-02       Impact factor: 9.139

4.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.

Authors:  J Vestbo; T Sørensen; P Lange; A Brix; P Torre; K Viskum
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

5.  Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects.

Authors:  S Yende; G W Waterer; E A Tolley; A B Newman; D C Bauer; D R Taaffe; R Jensen; R Crapo; S Rubin; M Nevitt; E M Simonsick; S Satterfield; T Harris; S B Kritchevsky
Journal:  Thorax       Date:  2005-11-11       Impact factor: 9.139

6.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

Authors:  R A Pauwels; C G Löfdahl; L A Laitinen; J P Schouten; D S Postma; N B Pride; S V Ohlsson
Journal:  N Engl J Med       Date:  1999-06-24       Impact factor: 91.245

7.  Lung function and glucose metabolism: an analysis of data from the Third National Health and Nutrition Examination Survey.

Authors:  Tricia M McKeever; Philip J Weston; Richard Hubbard; Andrew Fogarty
Journal:  Am J Epidemiol       Date:  2005-03-15       Impact factor: 4.897

8.  Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study.

Authors:  Rafea Shaaban; Sabine Kony; Fathi Driss; Bénédicte Leynaert; David Soussan; Isabelle Pin; Françoise Neukirch; Mahmoud Zureik
Journal:  Respir Med       Date:  2006-05-02       Impact factor: 3.415

9.  Plasma fibrinogen and lung function: the CARDIA Study.

Authors:  Bharat Thyagarajan; David R Jacobs; George G Apostol; Lewis J Smith; Cora E Lewis; O Dale Williams
Journal:  Int J Epidemiol       Date:  2006-03-22       Impact factor: 7.196

10.  Airway and systemic inflammation and decline in lung function in patients with COPD.

Authors:  Gavin C Donaldson; Terence A R Seemungal; Irem S Patel; Angshu Bhowmik; Tom M A Wilkinson; John R Hurst; Peter K Maccallum; Jadwiga A Wedzicha
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

View more
  55 in total

1.  Statin use reduces decline in lung function: VA Normative Aging Study.

Authors:  Stacey E Alexeeff; Augusto A Litonjua; David Sparrow; Pantel S Vokonas; Joel Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2007-08-02       Impact factor: 21.405

2.  Systemic inflammation and progression of COPD.

Authors:  Jørgen Vestbo
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

3.  Biomarkers in COPD: time for a deep breath.

Authors:  R A Stockley
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

4.  Association between AXL promoter methylation and lung function growth during adolescence.

Authors:  Lu Gao; Robert Urman; Joshua Millstein; Kimberly D Siegmund; Louis Dubeau; Carrie V Breton
Journal:  Epigenetics       Date:  2018-10-19       Impact factor: 4.528

5.  Systemic inflammation and reduced pulmonary function in chronic spinal cord injury.

Authors:  Eric Garshick; Kelly L Stolzmann; David R Gagnon; Leslie R Morse; Robert Brown
Journal:  PM R       Date:  2011-05       Impact factor: 2.298

6.  Gene promoter methylation is associated with lung function in the elderly: the Normative Aging Study.

Authors:  Johanna Lepeule; Andrea Baccarelli; Valeria Motta; Laura Cantone; Augusto A Litonjua; David Sparrow; Pantel S Vokonas; Joel Schwartz
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

Review 7.  Associations between statins and COPD: a systematic review.

Authors:  Claudia C Dobler; Keith K Wong; Guy B Marks
Journal:  BMC Pulm Med       Date:  2009-07-12       Impact factor: 3.317

8.  Systemic inflammation in chronic obstructive pulmonary disease: a population-based study.

Authors:  Francisco Garcia-Rio; Marc Miravitlles; Joan B Soriano; Luis Muñoz; Enric Duran-Tauleria; Guadalupe Sánchez; Víctor Sobradillo; Julio Ancochea
Journal:  Respir Res       Date:  2010-05-25

9.  Systemic inflammation in young adults is associated with abnormal lung function in middle age.

Authors:  Ravi Kalhan; Betty T Tran; Laura A Colangelo; Sharon R Rosenberg; Kiang Liu; Bharat Thyagarajan; David R Jacobs; Lewis J Smith
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

10.  The association between blood coagulation activity and lung function: a population-based study.

Authors:  Andrew W Fogarty; Sarah A Lewis; Tricia M McKeever; Gordon D O Lowe; Lorna Clark; John Britton
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.